A conversation with Frédéric Fiteni, Ph.D., medical oncologist and oncology PRO specialist, University Hospital of Nîmes, and, member of Kayentis Scientific Advisory Board.
“Listen to patients,” or a similar adage, is often repeated by clinical research professionals who see the value of patient input. Whether it’s to help review and revise informed consent documents, ensure the suitability of the study protocol, or determine study endpoints, patient feedback can greatly impact the viability and success of a clinical trial.
That’s if patients are indeed asked.
The challenge is of particular concern to medical oncologist Frédéric Fiteni, Ph.D., who says researchers just aren’t listening to patients when it comes to the value of quality of life (QoL) endpoints — even with the backing of regulatory bodies.
In this Q&A, Fiteni reveals the widespread industry reluctance to study QoL, describes the importance of QoL to patient satisfaction, and offers best practices for its integration.
Dr. Frédéric Fiteni, Ph.D. is a member of the Kayentis Scientific Advisory Board. He is a medical oncologist and oncology PRO specialist at the University Hospital of Nîmes – France and a lecturer at the University of Montpellier – France. Frédéric specializes in the treatment of breast and gynecological cancers.
Read the full interview in Clinical Leader 👇
